Curocell Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cost of Revenue	10.49	14.19
Gross Profit	-10.49	-14.19
Selling, General & Admin	4,632	3,821
Research & Development	31,864	27,191
Other Operating Expenses	14.51	11.22
Operating Expenses	36,614	31,116
Operating Income	-36,624	-31,130
Interest Expense	-2,603	-2,431
Interest & Investment Income	938.26	617.54
Currency Exchange Gain (Loss)	-24.34	-14.64
Other Non Operating Income (Expenses)	83.35	3,305
EBT Excluding Unusual Items	-38,230	-29,652
Gain (Loss) on Sale of Assets	-8.18	-11.24
Pretax Income	-38,238	-29,664
Income Tax Expense	1.1	-88.73
Net Income	-38,239	-29,575
Net Income to Common	-38,239	-29,575
Shares Outstanding (Basic)	14	12
Shares Outstanding (Diluted)	14	12
Shares Change (YoY)	18.10%	-
EPS (Basic)	-2736.00	-2499.00
EPS (Diluted)	-2736.00	-2499.00
Free Cash Flow	-28,863	-46,428
Free Cash Flow Per Share	-2065.13	-3923.04
EBITDA	-30,289	-26,424
D&A For EBITDA	6,335	4,706
EBIT	-36,624	-31,130
Advertising Expenses	43.48	45.38

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.